Literature DB >> 12734688

The classification of lymphomas: a new beginning or the end of an era?

A S Jack1.   

Abstract

The World Health Organisation Classification of Tumours of the Haematopoietic and Lymphoid Tissues has recently been published. This is the latest in a long line of classifications of haematological malignancies and will be the international standard. It is now possible to achieve high levels of diagnostic accuracy for the main types of lymphoma. However, many of the entities encompass a wide spectrum of clinical outcomes and this approach to classification may be insufficiently precise for the future needs of haematological oncology. Rapid progress in targeted therapies may require further developments in tumour classification based on pathogenic features rather than arbitrary morphological criteria.

Entities:  

Mesh:

Year:  2003        PMID: 12734688     DOI: 10.1007/s00259-003-1155-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  56 in total

Review 1.  Genetics of chronic lymphocytic leukaemia.

Authors:  T J Kipps
Journal:  Hematol Cell Ther       Date:  2000-06

2.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning.

Authors:  Margaret A Shipp; Ken N Ross; Pablo Tamayo; Andrew P Weng; Jeffery L Kutok; Ricardo C T Aguiar; Michelle Gaasenbeek; Michael Angelo; Michael Reich; Geraldine S Pinkus; Tane S Ray; Margaret A Koval; Kim W Last; Andrew Norton; T Andrew Lister; Jill Mesirov; Donna S Neuberg; Eric S Lander; Jon C Aster; Todd R Golub
Journal:  Nat Med       Date:  2002-01       Impact factor: 53.440

3.  Waldenström macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors.

Authors:  R G Owen; S L Barrans; S J Richards; S J O'Connor; J A Child; L A Parapia; G J Morgan; A S Jack
Journal:  Am J Clin Pathol       Date:  2001-09       Impact factor: 2.493

4.  The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells.

Authors:  A C Rawstron; J A Fenton; J Ashcroft; A English; R A Jones; S J Richards; G Pratt; R Owen; F E Davies; J A Child; A S Jack; G Morgan
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

5.  Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients.

Authors:  F Berger; P Felman; C Thieblemont; T Pradier; L Baseggio; P A Bryon; G Salles; E Callet-Bauchu; B Coiffier
Journal:  Blood       Date:  2000-03-15       Impact factor: 22.113

Review 6.  Molecular insights into the immunopathogenesis of follicular lymphoma.

Authors:  K Stamatopoulos; C Kosmas; C Belessi; N Stavroyianni; P Kyriazopoulos; T Papadaki
Journal:  Immunol Today       Date:  2000-06

7.  Mantle cell lymphoma: a cytopathological and immunocytochemical study.

Authors:  D Gagneten; Y M Hijazi; E S Jaffe; D Solomon
Journal:  Diagn Cytopathol       Date:  1996-02       Impact factor: 1.582

8.  p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas.

Authors:  M Pinyol; F Cobo; S Bea; P Jares; I Nayach; P L Fernandez; E Montserrat; A Cardesa; E Campo
Journal:  Blood       Date:  1998-04-15       Impact factor: 22.113

9.  Pathogenetic and clinical implications of Bcl-6 and Bcl-2 gene configuration in nodal diffuse large B-cell lymphomas.

Authors:  E Pescarmona; V De Sanctis; A Pistilli; A Pacchiarotti; M Martelli; C Guglielmi; F Mandelli; C D Baroni; F Le Coco
Journal:  J Pathol       Date:  1997-11       Impact factor: 7.996

Review 10.  Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis.

Authors:  H Döhner; S Stilgenbauer; K Döhner; M Bentz; P Lichter
Journal:  J Mol Med (Berl)       Date:  1999-02       Impact factor: 4.599

View more
  1 in total

Review 1.  Positron emission tomography in the management of lymphomas: a summary.

Authors:  M J O'Doherty; P J Hoskin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-04-12       Impact factor: 9.236

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.